Australia · Delayed Price · Currency is AUD Genetic Signatures Earnings Call Transcripts
Fiscal Year 2026
-
FY 2026 saw a 7% revenue decline to AUD 14.8 million, but net loss narrowed by 30% and cash outflow dropped significantly. Cost savings from restructuring and new long-term contracts support a stable outlook, with APAC and EMEA targeted for future growth.
-
A comprehensive restructuring delivered AUD 5 million in annualized cost savings and reset leadership, while product upgrades and new supply agreements strengthened positions in EMEA and Australia. U.S. market entry and major instrument projects are paused pending strategic review.
-
Revenue rose slightly to AUD 8.7 million, but gross margin declined due to higher costs. U.S. expansion remains a focus, with new customers and product development underway, while a forensic review targets cost reductions to address high cash burn.
Fiscal Year 2025
-
Revenue grew 63% to $15.9M with gross margin at 55%, driven by strong respiratory and EMEA sales. Strategic refocus, new automation partnerships, and disciplined cost management position the company for future growth despite a $20.1M loss and slower U.S. uptake.
-
Sales rose 136% year-over-year, with gross margin up to 59% and a statutory loss impacted by a one-time impairment. The first U.S. contract was secured, a strong pipeline is in place, and cash reserves exceed AUD 40.7 million.